company background image
ANIX logo

Anixa Biosciences NasdaqCM:ANIX Stock Report

Last Price

US$3.10

Market Cap

US$98.9m

7D

-3.7%

1Y

-37.5%

Updated

18 Apr, 2024

Data

Company Financials +

Anixa Biosciences, Inc.

NasdaqCM:ANIX Stock Report

Market Cap: US$98.9m

ANIX Stock Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.

ANIX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Anixa Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anixa Biosciences
Historical stock prices
Current Share PriceUS$3.10
52 Week HighUS$5.13
52 Week LowUS$2.75
Beta0.87
1 Month Change-13.89%
3 Month Change-37.50%
1 Year Change-37.50%
3 Year Change-28.41%
5 Year Change-26.01%
Change since IPO-93.64%

Recent News & Updates

Recent updates

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Jan 19
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27
Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28
Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

Shareholder Returns

ANIXUS BiotechsUS Market
7D-3.7%-4.2%-3.7%
1Y-37.5%-2.0%20.5%

Return vs Industry: ANIX underperformed the US Biotechs industry which returned -2% over the past year.

Return vs Market: ANIX underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is ANIX's price volatile compared to industry and market?
ANIX volatility
ANIX Average Weekly Movement9.1%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.0%

Stable Share Price: ANIX's share price has been volatile over the past 3 months.

Volatility Over Time: ANIX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19825Amit Kumarwww.anixa.com

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.

Anixa Biosciences, Inc. Fundamentals Summary

How do Anixa Biosciences's earnings and revenue compare to its market cap?
ANIX fundamental statistics
Market capUS$98.89m
Earnings (TTM)-US$10.74m
Revenue (TTM)US$210.00k

470.9x

P/S Ratio

-9.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANIX income statement (TTM)
RevenueUS$210.00k
Cost of RevenueUS$161.00k
Gross ProfitUS$49.00k
Other ExpensesUS$10.79m
Earnings-US$10.74m

Last Reported Earnings

Jan 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin23.33%
Net Profit Margin-5,116.19%
Debt/Equity Ratio0%

How did ANIX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.